Data on Rafael Pharmaceuticals’ CPI-613® (devimistat) in Patients with Relapsed Burkitt Lymphoma to be Presented at the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition

World News: . []

Cranbury, NJ, Dec. 03, 2019 (GLOBE NEWSWIRE) -- (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today that Ariela Noy, M.D., hematologic oncologist at and principal investigator on a of CPI-613® (devimistat) for patients with relapsed or refractory Burkitt lymphoma/leukemia or high-grade B-Cell lymphoma, will lead a at the . 

Dr. Noy will discuss how devimistat works in patients with Burkitt lymphoma, designed to cause cancer cell death by disrupting the enzyme activity of cancer cells. She will address the currently dismal prognosis for relapsed Burkitt lymphoma, as well as the study design and method of testing devimistat in patients.

The Annual ASH Meeting and Exposition will be held in Orlando, Florida from Dec. 7 through 10. ASH has more than 17,000 members from more than 100 countries and is the largest society serving both clinicians and scientists around the world who are working to conquer blood diseases.

In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements.

Disclosure: Dr. Ariela Noy receives research funding from Raphael Pharmaceuticals, Inc.

###

More news and information about Rafael Pharmaceuticals, Inc.

Published By:

Globe Newswire: 15:00 GMT Tuesday 3rd December 2019

Published: .

Search for other references to "data" on SPi News


Share

Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
 
Privacy Policy | Terms and Conditions | Contact Us